Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra, a semaglutide injection, cutting the monthly cost from ₹8,790 (approximately $106 USD) to ₹3,999 (approximately $48 USD). This move aims to improve access to obesity treatments in India, where obesity is increasingly recognized as a public health issue. The new pricing will take effect on April 3, 2026, and applies to all dosage strengths, with reductions averaging 47% for higher doses. This announcement follows the expiration of the patent for semaglutide, previously held by Danish pharmaceutical company Novo Nordisk, which has led to a surge in competition as other companies introduce cheaper alternatives. Investment bank Jefferies has highlighted the potential for the semaglutide market in India to reach $1 billion, contingent on effective pricing strategies and patient uptake. Emcure's CEO, Satish Mehta, emphasized that this price revision is a step towards making scientifically validated weight-management therapies accessible to a broader patient base.